Edition:
India

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

82.68USD
23 May 2018
Change (% chg)

$0.46 (+0.56%)
Prev Close
$82.22
Open
$82.03
Day's High
$82.91
Day's Low
$81.95
Volume
724,826
Avg. Vol
1,360,365
52-wk High
$89.07
52-wk Low
$73.70

Select another date:

Mon, May 14 2018

Photo

Lilly to buy cancer drug developer AurKa Pharma

Eli Lilly and Co will buy AurKa Pharma Inc in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately-held firm's experimental cancer treatment for solid tumors.

Eli Lilly to buy cancer drug developer AurKa Pharma

May 14 Drugmaker Eli Lilly and Co said on Monday it would buy AurKa Pharma Inc to get access to the privately-held company's experimental cancer treatment for solid tumors.

Lilly to buy Armo Biosciences for $1.6 billion to bolster cancer pipeline

Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to expand its portfolio of drugs that helps body's immune system fight cancer as the U.S. drugmaker chases rivals in a lucrative market.

Lilly to buy Armo Biosciences for $1.6 bln

May 10 Drugmaker Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to get access to the drug developer's experimental cancer treatment.

BRIEF-Elanco Animal Health Announces Addition Of General Counsel

* ELANCO ANIMAL HEALTH - NAMED MICHAEL-BRYANT HICKS AS GENERAL COUNSEL

BRIEF-Eli Lilly Shareholders Elect The 5 Nominees For Director To 3-Yr Terms Ending In 2021

* ELI LILLY SAYS THE 5 NOMINEES FOR DIRECTOR WERE ELECTED TO SERVE 3-YEAR TERMS ENDING IN 2021 BY VOTING SHAREHOLDERS AT 2018 ANNUAL MEETING - SEC FILING Source text: (http://bit.ly/2jGhwcQ) Further company coverage:

BRIEF-Lilly Endowment Reports Open Market Sale Of Shares Of Eli Lilly'S Common Stock

* LILLY ENDOWMENT REPORTS OPEN MARKET SALE OF 178,900 SHARES OF ELI LILLY AND CO'S COMMON STOCK AT AVERAGE PRICE OF $80.85PER SHARE ON APRIL 25 - SEC FILING

FDA panel against higher dose of Lilly-Incyte arthritis drug

An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.

BRIEF-Eli Lilly Interested In Immuno-Oncology Deals

* ELI LILLY AND CO CEO SAYS PLANS TO SHARE FINDINGS OF STRATEGIC REVIEW OF ANIMAL HEALTH BUSINESS IN JULY

Drugmaker Eli Lilly posts quarterly profit

April 24 U.S. drugmaker Eli Lilly and Co reported a quarterly profit on Tuesday on higher demand for its newer treatments such as its diabetes drug Trulicity and psoriasis medicine Taltz.

Select another date: